Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab

• Prif Awduron: Nicoletta Colombo (Awdur), Domenica Lorusso (Awdur), Bradley J. Monk (Awdur), Brian Slomovitz (Awdur), Kosei Hasegawa (Awdur), Angélica Nogueira-Rodrigues (Awdur), Melissa Zale (Awdur), Chinyere E. Okpara (Awdur), Gianmaria Barresi (Awdur), Jodi McKenzie (Awdur), Vicky Makker (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: LLC "MEDIAFORMAT", 2023-12-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Background. Lenvatinib plus pembrolizumab significantly improved efficacy compared with chemotherapy in patients with advanced endometrial cancer (aEC) regardless of microsatellite instability status or histologic subtype, who had disease progression following prior platinum-based therapy, in Study-...